Claims for Patent: 8,394,377
✉ Email this page to a colleague
Summary for Patent: 8,394,377
Title: | Methods for treating cancer using combination therapy |
Abstract: | The invention relates to methods for treating a subject by manipulating HER-2 on a cell as well as related products. The methods include methods of treating cancer using fatty acid oxidation inhibitors and HER-2 binding molecules such as antibodies and fragments thereof. |
Inventor(s): | Newell; Martha Karen (Holland, TX), Cabrera; Joshua Hunter (Colorado Springs, CO) |
Assignee: | The Regents of the University of Colorado (Denver, CO) |
Application Number: | 12/918,741 |
Patent Claims: | 1. A method of treating breast cancer, comprising: administering to a subject having breast cancer an effective amount of etomoxir and an anti-human epidermal growth factor
receptor 2 (HER-2) antibody to treat the breast cancer, wherein the antibody is trastuzumab further comprising identifying the subject as a subject that has a HER-2 lo/ negative cancer.
2. The method of claim 1, further comprising administering a fatty acid oxidation inhibitor comprising at least one of cerulenin, 5-(tetradecyloxy)-2-firoic acid, oxfenicine, methyl palmoxirate, metoprolol, amiodarone, perhexiline, aminocarnitine, hydrazonopropionic acid, 4-bromocrotonic acid, trimetazidine, ranolazine, hypoglycin, dichloroacetate, methylene cyclopropyl acetic acid, or beta-hydroxy butyrate. 3. The method of claim 1, wherein the cancer is a HER-2 lo/negative cancer. 4. The method of claim 1, further comprising administering a chemotherapeutic agent to the subject. 5. The method of claim 1, further comprising administering a glycolytic inhibitor to the subject. 6. The method of claim 1, wherein the anti-HER-2 antibody is a humanized monoclonal antibody. 7. A method of treating cancer comprising: administering to a subject having a HER-2 lo/negative cancer an effective amount of etomoxir to induce expression of HER-2 on a cancer cell and an anti-HER-2 antibody, wherein the antibody is trastuzumab and wherein the cancer is a breast cancer and wherein the cancer is resistance to chemotherapy. 8. The method of claim 7, further comprising administering a fatty acid oxidation inhibitor comprising at least one of cerulenin, 5-(tetradecyloxy)-2-furoic acid, oxfenicine, methyl palmoxirate, metoprolol, amiodarone, perhexiline, aminocarnitine, hydrazonopropionic acid, 4-bromocrotonic acid, trimetazidine, ranolazine, hypoglycin, dichloroacetate, methylene cyclopropyl acetic acid, or beta-hydroxy butyrate. 9. The method of claim 7, further comprising administering a chemotherapeutic agent to the subject. 10. The method of claim 7, further comprising administering a glycolytic inhibitor to the subject. 11. The method of claim 7, wherein the anti-HER-2 antibody is a humanized monoclonal antibody. 12. A method, comprising: identifying a subject having a HER-2 lo/negative cancer, wherein the cancer is a breast cancer, and administering to the subject an effective amount of etomoxir to induce expression of HER-2 on a breast cancer cell. 13. A method for inducing expression of HER-2 on a breast cancer cell, comprising contacting the breast cancer cell with an effective amount of a etomoxir to induce expression of HER-2 on the breast cancer cell. |
Details for Patent 8,394,377
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2028-02-21 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2028-02-21 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2028-02-21 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.